Incidence and time course of extrapyramidal symptoms with oral and long-acting injectable paliperidone: a posthoc pooled analysis of seven randomized controlled studies
Srihari Gopal,1 Yanning Liu,1 Larry Alphs,2 Adam Savitz,1 Isaac Nuamah,1 David Hough1 1Janssen Research and Development, LLC, Raritan, 2Janssen Scientific Affairs, LLC, Titusville, NJ, USA Background: The purpose of this study was to compare incidence rates and time course of extrapyramidal symptom...
Guardado en:
Autores principales: | Gopal S, Liu Y, Alphs L, Savitz A, Nuamah I, Hough D |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2013
|
Materias: | |
Acceso en línea: | https://doaj.org/article/b9ffb1d7273f4a3cab9a286406304619 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Time to onset and time to resolution of extrapyramidal symptoms in patients with exacerbated schizophrenia treated with 3-monthly vs once-monthly paliperidone palmitate
por: Mathews M, et al.
Publicado: (2018) -
Caregiver burden in schizophrenia following paliperidone palmitate long acting injectables treatment: pooled analysis of two double-blind randomized phase three studies
por: Srihari Gopal, et al.
Publicado: (2017) -
Long-lasting extrapyramidal symptoms after multiple injections of paliperidone palmitate to treat schizophrenia
por: Takada R, et al.
Publicado: (2018) -
Efficacy and safety of paliperidone palmitate 3-month versus 1-month formulation in patients with schizophrenia: comparison between European and non-European population
por: Savitz AJ, et al.
Publicado: (2019) -
Expansion of guidance for the day 8 initiation dose of paliperidone palmitate to avoid a missed dose
por: Samtani MN, et al.
Publicado: (2013)